Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 10.

Felip, E., Minotti, V., Soo, R., Wolf, J., Solomon, B., Tan, D. S. W., Ardizzoni, A., Lee, D. H., Sequist, L. V., Barlesi, F., Paz-Ares, L., Rodriguez-Abreu, D., Garcia Campelo, M. R., Sprauten, M., Djentuh, L. O'Sullivan, Belli, R., Glaser, S., Zou, M., Giovannini, M. and Yang, J. C-H. (2020). MET inhibitor capmatinib plus EGFR tyrosine kinase inhibitor nazartinib for EGFR-mutant non-small cell lung cancer. Ann. Oncol., 31. S. S829 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Felip, E., Van Meerbeeck, J., Wolf, J., Ardizzoni, A., Li, A., Srinivasan, S. and Popat, S. (2016). CheckMate 171: A multicenter phase 2 trial of nivolumab (nivo) in patients (pts) with stage IIIB/IV squamous cell (SQ) NSCLC who have received >= 1 prior systemic treatment. J. Thorac. Oncol., 11 (4). S. S141 - 1. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1556-1380

Kim, D., Mehra, R., Tan, D. S. W., Felip, E., Chow, L. Q. M., Camidge, D. R., Vansteenkiste, J., Sharma, S., De Pas, T., Riely, G. J., Solomon, B. J., Wolf, J., Thomas, M., Schuler, M., Liu, G., Santoro, A., Geraldes, M., Boral, A. L., Yovine, A. and Shaw, A. T. (2014). Efficacy and Safety of Ceritinib in Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Rearranged (ALK plus ) Non-Small Cell Lung Cancer (NSCLC): An Update of ASCEND-1. Int. J. Radiat. Oncol. Biol. Phys., 90. S. S33 - 2. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1879-355X

Michels, S., Thurat, M., Schmalz, P., Pereira, E., Scheffler, M., Fischer, R., Sebastian, M., Abreu, D. R., Carcereny, E., Corral, J. J., Felip, E., Grohe, C., Insa, A., Thomas, M., Reck, M., Rothschild, S., Brandes, V, Nogova, L., Merkelbach-Bruse, S., Massuti, B., Buettner, R., Rosell, R. and Wolf, J. (2016). EUCROSS: A European phase II trial to evaluate efficacy and safety of crizotinib treatment in advanced adenocarcinoma of the lung harbouring ROS1 translocations - Preliminary results. Oncol. Res. Treat., 39. S. 209 - 211. BASEL: KARGER. ISSN 2296-5262

Passaro, A., Leighl, N., Blackhall, F., Popat, S., Kerr, K., Ahn, M. J., Arcila, M. E., Arrieta, O., Planchard, D., de Marinis, F., Dingemans, A. M., Dziadziuszko, R., Faivre-Finn, C., Feldman, J., Felip, E., Curigliano, G., Herbst, R., Janne, P. A., John, T., Mitsudomi, T., Mok, T., Normanno, N., Paz-Ares, L., Ramalingam, S., Sequist, L., Vansteenkiste, J., Wistuba, I. I., Wolf, J., Wu, Y. L., Yang, S. R., Yang, J. C. H., Yatabe, Y., Pentheroudakis, G. and Peters, S. (2022). ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer. Ann. Oncol., 33 (5). S. 466 - 488. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Reck, M., Spira, A., Besse, B., Wolf, J., Skoulidis, F., Borghaei, H., Goto, K., Park, K., Griesinger, F., Felip, E., Boyer, M., Barrios, C. H., Goss, G., Yang, H., Obiozor, C. and Ramalingam, S. S. (2020). CodeBreak 200: A phase III multicenter study of sotorasib (AMG 510), a KRAS(G12C) inhibitor, versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC) harboring KRAS p.G12C mutation. Ann. Oncol., 31. S. S894 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Tan, D. S., Kim, S-W., Sequist, L. V., Ponce Aix, S., Smit, E. F., Hida, T., Yang, J. C-H., Felip, E., Seto, T., Grohe, C., Wolf, J., Ko, J., Marriere, E., Belli, R., Giovannini, M. and Kim, D-W. (2018). Phase II results for single-agent nazartinib (EGF816) in adult patients (pts) with treatment-naive EGFR-mutant non-small cell lung cancer (NSCLC). Ann. Oncol., 29. S. 748 - 749. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Wolf, J., Han, J., Nishio, M., Souquet, P., Paz-Ares, L., De Marinis, F., Seto, T., De Jonge, M., Kim, T. M., Vansteenkiste, J., Tan, D., Garon, E., Groen, H., Hochmair, M., Felip, E., Reguart, N., Thomas, M., Overbeck, T., Ohashi, K., Giovannini, M., Yura, R., Joshi, A., Akimov, M. and Heist, R. (2017). GEOMETRY Mono-1: Phase II, Multicenter Study of MET Inhibitor Capmatinib (INC280) in EGFR Wt, MET-Dysregulated Advanced NSCLC. J. Thorac. Oncol., 12 (11). S. S2399 - 1. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1556-1380

Wolf, J., Han, J., Nishio, M., Souquet, P., Paz-Ares, L., De Marinis, F., Seto, T., De Jonge, M., Kim, T. M., Vansteenkiste, J., Tan, D. S. W., Garon, E. B., Groen, H., Hochmair, M. J., Felip, E., Reguart, N., Thomas, M., Overbeck, T., Ohashi, K., Giovannini, M., Yura, R., Joshi, A., Akimov, M. and Heist, R. (2017). GEOMETRY Mono-1: Phase II, Multicenter Study of MET Inhibitor Capmatinib (INC280) in EGFR wt, MET-dysregulated Advanced NSCLC. J. Thorac. Oncol., 12 (11). S. S1578 - 2. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1556-1380

Wolf, J., Hochmair, M., Kattan, J. G., Ang, M. -K., Garon, E. B., Groen, H. J. M., Heist, R., Ohashi, K., Felip, E., Reguart, N., Garcia Campelo, R., Soo, R., Paz-Ares, L., de Marinis, F., Smit, E. F., Giovannini, M., Squires, M., Cui, X., Zhang, Y. and Tan, D. (2015). A phase II, multicenter, four-cohort study of oral cMET inhibitor capmatinib (INC280) in patients with EGFR wild-type, advanced NSCLC who have received one or two prior lines of systemic therapy for advanced/metastatic disease. Ann. Oncol., 26. S. 146 - 147. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

This list was generated on Tue Jul 23 13:00:36 2024 CEST.